Advancing Cancer Treatment
The Therapeutics Discovery division at 体育app was created to eliminate the bottlenecks that hamper traditional drug development.
Our team of more than 100 dedicated cancer researchers, doctors, drug developers and scientific experts develops small molecule drugs, biologics and cellular therapies, inspired by the needs of 体育app cancer patients and guided by the expertise of the center’s clinicians. To create life-saving transformational medicines quickly, safely and effectively, Therapeutics Discovery works with unparalleled proximity to patients and an unmatched wealth of clinical experience.
Therapeutics Discovery doesn’t bring the “bench to bedside” – it starts with the bench at the bedside – with each patient and their cancer.
The platforms of Therapeutics Discovery are supported by 体育app’s Moon Shots Program?.
We have leveraged our unique approach to discover and advance novel small-molecule, biologic and cell-based therapies to answer unmet needs that will improve the lives of our patients.Learn more about our therapeutics pipeline
In the News
Stay up to date on our new collaborations and recent progress.
The University of Texas 体育app Cancer Center and today announced a multi-year strategic collaboration designed to expedite the research and development of novel engineered tumor infiltrating lymphocytes (TILs) for the treatment of solid tumors. The agreement pairs Obsidian and its novel cytoDRiVE? technology platform with MD?Anderson’s extensive experience and state-of-the-art capabilities in TIL cell therapy, led by the Biologics Development platform, within the Therapeutics Discovery division.
The collaboration is focused on developing TIL armored with regulated membrane-bound IL15 (referred to as cytoTIL?) with the potential to enhance anti-tumor efficacy and reduce tumor burden in patients suffering from different types of solid tumors. The teams will collaborate to accelerate the development of cytoTIL, including process and analytical development and clinical readiness activities.
“TIL therapy has emerged as a promising option for treating patients with solid tumors, though its widespread use today is limited by safety and efficacy challenges,” said , associate professor of Melanoma Medical Oncology at 体育app. “We are pleased to work with Obsidian to advance their novel cytoTIL program, which has the potential to drive more durable treatment responses and expand TIL therapy to a broader group of our patients.”??
The cytoTIL therapy is engineered using Obsidian's cytoDRiVE platform technology, which precisely and reversibly controls protein expression and activity using FDA-approved orally bioavailable drugs. By leveraging regulated membrane-bound IL15 to drive antigen-independent expansion of T cells and transactivation of NK cells, cytoTIL therapy is anticipated to improve patient response to TIL treatment and expand patient eligibility to those who currently cannot benefit from this transformative therapy.
“We are delighted to work with MD Anderson’s Biologics Development team to build upon the success of first generation TIL therapies and bring the first controllable TIL therapy to patients as rapidly as possible,” said , CEO of Obsidian Therapeutics. “Through its cell therapy research platforms, deep clinical development experience, and industrial manufacturing capabilities, 体育app is a best-in-class collaborator to advance and accelerate cutting-edge cell therapies.”
体育app’s Biologics Development
platform is built around an experienced team focused on pioneering
impactful biologic therapeutics, including antibodies and cell
therapies. With a state-of-the-art 60,000 sq. foot GMP cell-therapy
manufacturing facility, the platform joins MD
Anderson expertise with the rigor of industrial development.
Biologics Development offers a strong starting point for early-stage
companies to access the breadth of MD
Anderson capabilities in cell therapy development.
体育app is implementing an?Institutional Conflict of Interest Management and Monitoring Plan?for any research related to this relationship.
and Taiho Pharmaceutical Co., Ltd., today announced a three-year strategic collaboration to accelerate the development of treatments for significant unmet medical needs in oncology, including patients with brain metastases and those with cancers refractory to available therapies.
This collaboration will bring Taiho’s unique portfolio of preclinical and clinical brain-penetrant therapies together with both the translational research capabilities of 体育app’s Translational Research to Advance Therapeutics and Innovation in Oncology (TRACTION) platform as well as insights and clinical development infrastructure from 体育app’s Brain Metastasis Clinic.
“Our collaboration with 体育app exemplifies a direct line of sight from target development to therapies for patients with limited treatment options,” said Teruhiro Utsugi, Ph.D., managing director at Taiho. “Investigating our novel portfolio of drug candidates in this innovative research structure will enable us to more rapidly identify and develop effective treatment strategies.”
According to the American Brain Tumor Association, metastases to the brain and spine are diagnosed in more than 200,000 patients annually in the US. However, the development of effective treatment approaches for these patients has been hampered because they often are excluded from clinical trials. However, recent studies in melanoma, lung and breast cancers have demonstrated that patients with brain metastases can gain significant clinical benefit from immunotherapy and targeted therapies, leading to improvements in quality of life and survival.
体育app’s Brain Metastasis Clinic is a patient-focused, multidisciplinary center designed to reduce the time from a diagnosis to treatment for patients with brain metastases while improving access to clinical trials. The TRACTION platform, an industry-scale translational research unit within 体育app’s Therapeutics Discovery division, has established a robust integrated research framework with the Brain Metastasis Clinic to identify innovative treatment approaches and execute novel clinical trials.
“体育app’s commitment to delivering novel therapeutic strategies to patients with unmet clinical needs is exemplified in the development of the Brain Metastasis Clinic and its close collaboration with the TRACTION platform,” said Timothy Heffernan, Ph.D., executive director of TRACTION at 体育app. “Our alliance with Taiho combines outstanding drug discovery with expertise in translational research and clinical development to advance new treatment options for patients diagnosed with brain metastases.”
Our Unique Model
We are a drug development engine built within 体育app, taking an approach unlike anywhere else. Our experienced teams work collaboratively across industry-scale research platforms to advance new therapies, and we collaborate with leading biopharmaceutical companies to bring new medicines to patients in need.Learn more about our approach
Join Our Team
We are seeking experienced individuals to join our team.
If you are interested in applying but not sure where to begin, submit your resume to firstname.lastname@example.org.
Or, for keywords "Therapeutics Discovery" to learn about our open positions and how to apply.